{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:27:03Z","timestamp":1755221223715,"version":"3.43.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Pancreas"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>S-1 monotherapy with concurrent radiotherapy (RT) is a standard of care for patients with locally advanced pancreatic cancer (LAPC). Although renal dysfunction increases S-1 monotherapy toxicity, its effect in S-1 with concurrent RT remains unknown. We evaluated the effect of renal function on the safety of S-1 with RT for LAPC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We performed an integrated exploratory post hoc analysis of data from 2 prospective studies (JCOG1106 and LAPC-S1RT), where patients with LAPC received RT (50.4 Gy\/28 fraction for 5.5 weeks) and concurrent S-1 (40 mg\/m<jats:sup>2<\/jats:sup> per dose, twice daily on the day of irradiation). We split the patients into high creatinine clearance (CCr; \u226580 mL\/min) and low CCr (&lt;80 mL\/min) groups and compared the findings to determine treatment safety.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The high and low CCr groups showed a median of 97.5 (range, 80.0\u2013194.6) and 64.4 (range, 50.0\u201378.3) mL\/min, respectively. The low CCr group presented more adverse reactions (ARs) of grade 3 or higher and gastrointestinal ARs of grade 2 or higher than the high CCr group (30.8% vs 15.8% and 51.9% vs 36.8%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The incidence of ARs associated with concurrent S-1 and RT increases in patients with low CCr; therefore, ARs should be duly considered in such patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mpa.0000000000001879","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T03:00:37Z","timestamp":1633921237000},"page":"965-971","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer"],"prefix":"10.1097","volume":"50","author":[{"given":"Satoshi","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gakuto","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Fukutomi","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagaizumi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tosiya","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Kyoto University School of Public Health, Kyoto City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Showa University School of Medicine, Shinagawa City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Kadota","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Ioka","sequence":"additional","affiliation":[{"name":"Department of Cancer Survey and Gastrointestinal Oncology, Osaka International Cancer Center, Osaka City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Sugimori","sequence":"additional","affiliation":[{"name":"Gastroenterological Center, Yokohama City University Medical Center, Yokohama City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Sata","sequence":"additional","affiliation":[{"name":"Department of Surgery, Jichi Medical University, Simono City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Nakamori","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Osaka National Hospital, Osaka City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tokyo Women's Medical University Hospital, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobumasa","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ishii","sequence":"additional","affiliation":[{"name":"Gastrointestinal Medical Oncology, Chiba Cancer Center, Chiba City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kyorin University Faculty of Medicine, Mitaka City, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib4-20250808","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/MPA.0000000000001513","article-title":"Clinical practice guidelines for pancreatic cancer 2019 from the Japan Pancreas Society: a synopsis","volume":"49","year":"2020","journal-title":"Pancreas"},{"key":"bib5-20250808","first-page":"2602","article-title":"Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats","volume":"56","year":"1996","journal-title":"Cancer Res"},{"key":"bib6-20250808","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"bib7-20250808","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial","volume":"9","year":"2008","journal-title":"Lancet Oncol"},{"key":"bib8-20250808","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S1470-2045(13)70490-X","article-title":"Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial","volume":"14","year":"2013","journal-title":"Lancet Oncol"},{"key":"bib9-20250808","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijrobp.2010.01.027","article-title":"Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer","volume":"80","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib10-20250808","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00534-011-0400-y","article-title":"A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer","volume":"19","year":"2012","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"bib11-20250808","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00280-008-0836-1","article-title":"Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer","volume":"63","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"bib12-20250808","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijrobp.2012.03.059","article-title":"A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer","volume":"85","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib14-20250808","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jjco\/hyaa198","article-title":"Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106","volume":"51","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"bib15-20250808","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-003-0617-9","article-title":"Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors","volume":"52","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"bib16-20250808","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s10120-004-0306-3","article-title":"Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer","volume":"8","year":"2005","journal-title":"Gastric Cancer"},{"key":"bib17-20250808","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10120-007-0422-y","article-title":"Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer","volume":"10","year":"2007","journal-title":"Gastric Cancer"},{"key":"bib18-20250808","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10120-012-0158-1","article-title":"Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer","volume":"16","year":"2013","journal-title":"Gastric Cancer"},{"key":"bib19-20250808","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","article-title":"Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"key":"bib20-20250808","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","year":"1976","journal-title":"Nephron"},{"key":"bib22-20250808","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7150\/jca.11189","article-title":"Risk factors for discontinuation of S-1 adjuvant chemotherapy for gastric cancer","volume":"6","year":"2015","journal-title":"J Cancer"},{"key":"bib23-20250808","first-page":"229","article-title":"Pancreatic cancer and diabetes","volume":"771","year":"2012","journal-title":"Adv Exp Med Biol"},{"key":"bib24-20250808","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jama.1995.03520440059037","article-title":"Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis","volume":"273","year":"1995","journal-title":"JAMA"},{"key":"bib25-20250808","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1038\/sj.bjc.6602619","article-title":"Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies","volume":"92","year":"2005","journal-title":"Br J Cancer"},{"key":"bib26-20250808","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.ejca.2011.03.003","article-title":"Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies","volume":"47","year":"2011","journal-title":"Eur J Cancer"},{"key":"bib27-20250808","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00280-008-0741-7","article-title":"A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer","volume":"63","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"bib28-20250808","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00280-007-0514-8","article-title":"A late phase II study of S-1 for metastatic pancreatic cancer","volume":"61","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"bib29-20250808","first-page":"2000","article-title":"Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug","volume":"5","year":"1999","journal-title":"Clin Cancer Res"},{"key":"bib30-20250808","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S2468-1253(19)30327-9","article-title":"Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"bib31-20250808","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","article-title":"Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)","volume":"11","year":"2005","journal-title":"Clin Cancer Res"},{"key":"bib32-20250808","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","article-title":"A phase I clinical, plasma, and cellular pharmacology study of gemcitabine","volume":"9","year":"1991","journal-title":"J Clin Oncol"},{"key":"bib33-20250808","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"bib34-20250808","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPA.0000000000001879","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T11:04:18Z","timestamp":1754651058000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPA.0000000000001879"}},"subtitle":["An Integrated Analysis of Data From 2 Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0000000000001879","relation":{},"ISSN":["1536-4828","0885-3177"],"issn-type":[{"type":"electronic","value":"1536-4828"},{"type":"print","value":"0885-3177"}],"subject":[],"published":{"date-parts":[[2021,8]]}}}